Pyxis Oncology (PYXS) Income towards Parent Company (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Income towards Parent Company data on file, last reported at -$18.1 million in Q4 2025.

• Income towards Parent Company for Q4 2025 came in at -$18.1 million, up 49.06% year-over-year; the trailing twelve-month figure through Dec 2025 was -$79.9 million (down 0.57% YoY), and the FY2025 annual result was -$79.6 million, down 2.98% from the prior year.
• Income towards Parent Company grew to -$18.1 million in Q4 2025 per PYXS's latest filing, from -$22.0 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$5.3 million in Q1 2024 and troughed at -$36.1 million in Q4 2022.
• A 5-year average of -$21.3 million and a median of -$20.5 million in 2023 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company sank 330.7% in 2022, then jumped 73.13% in 2024.
• A 5-year view of Income towards Parent Company shows it stood at -$16.4 million in 2021, then slumped by 119.87% to -$36.1 million in 2022, then surged by 55.2% to -$16.2 million in 2023, then plunged by 119.94% to -$35.6 million in 2024, then jumped by 49.06% to -$18.1 million in 2025.
• Business Quant data shows PYXS's Income towards Parent Company at -$18.1 million in Q4 2025, -$22.0 million in Q3 2025, and -$18.1 million in Q2 2025.